R2

Sanofi’s Tzield moves type 1 diabetes into disease modification, but access may decide who benefits

Measles Deaths in England Expose the Cost of Missed Protection

Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies

AMR Stewardship Starts Before the Antibiotic Is Prescribed

World Cup Health Guidance Turns Football Into a Public-Health Test

Not All Eye Infections Are Equal: New Evidence Points to a Precision Medicine Approach

As GLP-1 use expands, healthcare systems are confronting a new challenge: balancing obesity treatment with rising concerns about eating disorders and patient safety.

GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race

J&J’s Firefly Bio Deal Puts KRAS Back Into the Oncology Arms Race
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
